OncoZenge is developing BupiZenge, a lozenge based on the safe and effective, non-opioid long-acting pain reliever bupivacaine. BupiZenge’s primary indication is oral mucositis and it has the potential to help millions of people with their oral pain caused by radiotherapy and chemotherapy
We are pleased to present our Annual Reports. These reports encapsulates our financial performance and strategic initiatives (Swedish only).
Annual report 2022
Annual report 2021
Annual report 2020
We are delighted to share our quarterly reports. These reports provide insights into our recent financial performance, operational highlights, and strategic milestones, reflecting our ongoing dedication to transparency and excellence.